RxDoctor Payments Data

Kelci Hensley, PA

Physician Assistant · Adrian, MINPI 1841655503

Payments from drug & device makers

$1,728in general payments, 2019–2025

Across 95 payments — averaging $18.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$395
  • Lilly USA, LLC$381
  • Pfizer$212
  • Actelion Pharmaceuticals US, Inc.$121
  • AbbVie$85
  • Bayer$79
  • plus $456 from 13 others

What the payments were for

  • Food & beverage$1,60793%
  • Education$1207%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,728 in reported general payments places this provider in the 80th percentile of 5,453 physician assistant providers in Michigan.

See all physician assistant providers in Michigan

Medicare billing

Part B allowed, 2024
$67,409
Medicare patients
183
Services billed
928

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide96$162,845
JardianceEmpagliflozin55$56,356
EliquisApixaban43$55,829
OzempicSemaglutide42$42,056
JanuviaSitagliptin Phosphate20$24,879
XareltoRivaroxaban18$18,895
MounjaroTirzepatide17$17,614
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$15,511
Lantus SolostarInsulin Glargine,hum.Rec.Anlog83$14,296
Levemir FlexpenInsulin Detemir19$10,736
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog27$9,310
Atorvastatin Calcium444$6,127
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$5,867
FarxigaDapagliflozin Propanediol11$5,848
Albuterol Sulfate HfaAlbuterol Sulfate129$3,716

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$381$180,459113 claims
PfizerEliquis$212$55,82943 claims
Novo NordiskOzempic$395$42,05642 claims
GSKTrelegy Ellipta, Anoro Ellipta$76$21,37833 claims
AstraZenecaFarxiga$44$5,84811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 5,453 physician assistant providers in Michigan.

Other physician assistant in Adrian

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →